Table 2.
Age-standardized incidence for invasive and non-invasive breast cancer during the pandemic and reference years.
| Site | Subgroupa | Incidence (95% CI) in the calendar yearb | Comparison to 2018/2019 | |||
|---|---|---|---|---|---|---|
| ICD-10 | 2018/2019 | 2020 | 2021 | IRR 2020 (95% CI) | IRR 2021 (95% CI) | |
| C50 | All | 170.9 (168.5–173.3) | 159.7 (156.5–163.0) | 169.2 (165.9–172.6) | 0.93 (0.91–0.96) | 0.99 (0.97–1.01) |
| Age < 50 | 48.7 (47.0–50.4) | 46.9 (44.5–49.4) | 50.2 (47.7–52.7) | 0.96 (0.90–1.02) | 1.03 (0.97–1.09) | |
| Age 50–59 | 256.6 (249.1–264.2) | 244.6 (234.3–255.2) | 258.9 (248.3–269.9) | 0.95 (0.91–1.00) | 1.01 (0.96–1.06) | |
| Age 60–69 | 355.3 (345.3–365.6) | 310.5 (297.5–323.9) | 351.2 (337.5–365.3) | 0.87 (0.83–0.92) | 0.99 (0.94–1.04) | |
| Age 70–79 | 378.1 (366.2–390.2) | 368.0 (351.5–385.1) | 375.7 (358.9–393.1) | 0.97 (0.92–1.03) | 0.99 (0.94–1.05) | |
| Age 80 + | 401.7 (388.2–415.6) | 374.0 (356.2–392.4) | 369.7 (352.3–387.7) | 0.93 (0.88–0.99) | 0.92 (0.87–0.98) | |
| Stage I | 59.3 (57.9–60.7) | 54.7 (52.8–56.7) | 59.3 (57.3–61.3) | 0.92 (0.88–0.96) | 1.00 (0.96–1.04) | |
| Stage II | 59.9 (58.5–61.3) | 55.5 (53.6–57.5) | 57.2 (55.3–59.2) | 0.93 (0.89–0.97) | 0.96 (0.92–1.00) | |
| Stage III | 15.9 (15.2–16.6) | 14.0 (13.1–15.0) | 14.4 (13.4–15.4) | 0.88 (0.81–0.95) | 0.91 (0.84–0.99) | |
| Stage IV | 11.6 (11.0–12.2) | 11.4 (10.6–12.3) | 11.7 (10.8–12.6) | 0.99 (0.90–1.08) | 1.01 (0.92–1.11) | |
| Stage X | 20.7 (19.9–21.6) | 21.4 (20.2–22.6) | 22.5 (21.3–23.8) | 1.03 (0.96–1.11) | 1.09 (1.02–1.17) | |
| D05 | All | 11.6 (11.0–12.3) | 9.8 (9.0–10.7) | 11.9 (11.0–12.8) | 0.85 (0.77–0.93) | 1.03 (0.94–1.13) |
| Age < 50 | 2.6 (2.2–3) | 2.2 (1.7–2.8) | 3.0 (2.4–3.7) | 0.88 (0.66–1.16) | 1.16 (0.90–1.50) | |
| Age 50–59 | 29.1 (26.6–31.7) | 24.4 (21.2–27.9) | 30.6 (27.0–34.5) | 0.84 (0.72–0.99) | 1.05 (0.91–1.22) | |
| Age 60–69 | 30.6 (27.7–33.7) | 26.1 (22.4–30.2) | 30.8 (26.9–35.2) | 0.85 (0.71–1.01) | 1.00 (0.85–1.18) | |
| Age 70–79 | 15.6 (13.2–18.2) | 12.9 (9.9–16.5) | 12.5 (9.6–16.0) | 0.83 (0.62–1.11) | 0.80 (0.60–1.08) | |
| Age 80 + | 7.3 (5.6–9.4) | 5.9 (3.8–8.7) | 8.8 (6.3–12.0) | 0.81 (0.51–1.29) | 1.21 (0.81–1.80) | |
IRR = incidence rate ratio, CI = confidence interval; significant values are printed in bold; a Subgroups by age at diagnosis and sex. In stage-specific analyses, 41 (0.1%) patients with tumors that were not classifiable by the UICC according to their histology and 848 patients whose death certificate was available (2.2%) were excluded. Patients without stage information were classified as stage X. b Incidence per 100.000 women.